Sign in →

Order Code LABUCTTHC Marijuana Metabolite, Umbilical Cord Tissue, Qualitative

Important Note

This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

Specimen Requirements

Collect:

Umbilical Cord (At least 8 inches, approximately the width of a sheet of paper.)
 

Specimen Preparation:

Drain and discard any blood. Rinse the exterior of the cord segment with normal saline or water. Pat the cord dry and transport at least 8 inches of umbilical cord in a routine urine collection cup.

Storage/Transport Temperature:
Refrigerated.

Unacceptable Conditions:
Cords soaking in blood or other fluid. Formalin fixed. Tissue that is obviously decomposed.

 

Stability:

Ambient: 1 week; Refrigerated: 3 weeks; Frozen: 1 year

Reference Values

Drugs/Drug Classes Cutoff Concentrations (ng/g)
THC-COOH 0.2

Day(s) Test Set Up

Sunday to Saturday

Turnaround time: 1-3 days after arrival at ARUP laboratory

Performing Laboratory

ARUP Reference Laboratory

Methodology

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

Test Classification and CPT Coding

80349 

Interpretive Data

This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite.  Alternative testing is available to detect other drug exposures.  The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
 

Compliance Category

Laboratory Developed Test (LDT)